News

The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...
Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...
The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for ...
Indian drugmaker Biocon (BSE: 532523) subsidiary Biocon Biologics has announced a settlement and license agreement with the ...
Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...
Retinal pigment epithelial detachment is associated with neovascular age-related macular degeneration in 30% to 80% of cases, according to the literature.It is often difficult to treat, requires a ...
Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US ...
Biocon Biologics secures market entry date for Yesafili, an interchangeable biosimilar to Eylea, in US: Our Bureau, Bengaluru Tuesday, April 15, 2025, 11:30 Hrs [IST] Biocon Biolo ...
Additionally, Biocon Biologics secured a settlement agreement in Canada with Bayer and Regeneron Pharma for launch of YESAFILI no later than July 1, 2025.
BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and ...